WeVote
Log In

Bill

Bill

HB 408

INSURANCE/HEALTH: Requires health insurance coverage relative to pediatric acute-onset neuropsychiatric syndrome and related conditions (EN INCREASE GF EX See Note)

2025 Regular Session Introduced by Dennis Bamburg and 51 co-sponsors

Louisiana requires health insurers to cover diagnosis and treatment of pediatric acute-onset neuropsychiatric syndrome, effective August 2025, expanding mental health coverage for children with sudden-onset psychiatric symptoms.

Signed by the Governor. Becomes Act No. 360.
0
WeVote Research Nonpartisan
Bill Summary · HB 408

Legislative bill overview

HB 408 mandates that health insurance plans in Louisiana provide coverage for the diagnosis and treatment of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and related conditions. The bill requires insurers to cover evidence-based diagnostic procedures and therapeutic interventions for these conditions without imposing exclusions or limitations that single them out compared to other mental health conditions.

Why is this important

PANS is a rare condition where children experience sudden-onset OCD, tics, anxiety, and other neuropsychiatric symptoms, often following infection. Without insurance coverage requirements, families face significant out-of-pocket costs for specialized evaluations and treatments. This mandate ensures affected families have equitable access to diagnosis and care that might otherwise be unavailable or financially devastating.

Potential points of contention

  • Medical consensus debate: PANS remains controversial in mainstream medicine, with limited peer-reviewed evidence and disagreement among medical societies about diagnostic criteria and treatment protocols, raising questions about mandating coverage for a condition lacking universal clinical acceptance
  • Cost implications: Requiring coverage for specialized diagnostics and treatments increases insurance premiums for all policyholders, with unclear data on how many Louisiana children would actually need these services
  • Treatment specificity concerns: The bill may create pressure to cover unproven or experimental treatments if patients and advocates argue they're necessary for PANS, even without robust clinical trial evidence

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.